EVALUATING OPTIONS OBJECTIVELY - RESISTING THE 'PURIST' APPROACH TO ARRIVE AT THE MOST PRODUCTIVE, ROBUST, AND PRACTICALLY IMPLEMENTABLE PERFUSION UTILIZING PROCESSES

摘要

Over the past three years our groups have been working collaboratively to help provide and define options for future high-intensity biopharmaceutical production processes - aka the Next-Generation MAb manufacturing process. Using perfusion/cell retention and a number of comparator cell lines generated using different expression systems and different proprietary media compositions, our presentation will focus on the comparison of different process options that move us closer to a high volumetric productivity yet practically implementable mode of bioreactor operation.